Same Indication

Ipilimumab vs Raltegravir

Ipilimumab vs Raltegravir: Overview

This comparison examines the pharmacological differences between Ipilimumab and Raltegravir.

Mechanism of Action

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Ipilimumab β€” 14.7 days.

Chemical Properties

Type: Ipilimumab β€” Antibody; Raltegravir β€” Small molecule.